Table 3.

Total population size of the benefit cohorts and numbers of cases of chronic disease averted

	Benefit cohort 1: Protected from acquiring infection and, therefore, subsequently protected from any clinical disease (millions)	Benefit cohort 2: Subclinical morbidity prevented from progressing (millions)	Benefit cohort 3: Clinical disease improved (millions)	Total (millions)
Population size
Hydrocele	16.23	9.26	9.37	34.86
Lymphedema	9.74	5.56	8.30	23.60
Total	25.97	14.82	17.67	58.46
Cases of chronic disease averted
Hydrocele	16.23	9.26	1.82	27.31
Lymphedema	9.74	5.56	1.64	16.93
Total	25.97	14.82	3.46	44.25

Note that the benefit cohorts quantify the individuals who are projected to benefit directly in terms of prevented or alleviated clinical disease by the treatments given between 2000–2020, i.e. they capture the long-term health benefits of these treatments beyond the year 2020